There has been an increasing interest in the development of animal models that address different types of @entity148 . The elevated T-maze (ETM) was developed based on the assumption that inhibitory avoidance and one-way escape are respectively related to @entity148 ( @entity148 ) and @entity4697 ( @entity4697 ). Although anxiolytic effects on the inhibitory avoidance task have been shown for drugs used in clinical settings to treat @entity148 , positive effects of antipanic drugs in one-way escape have been described only for @entity2645 . The study extends the pharmacological validation of the ETM to other @entity750 reuptake inhibitors that have antipanic properties. To this end, we investigated the effects of acute and chronic (21 days) IP administration of @entity8991 (3, 10 and 30 mg/kg) and @entity905 (5, 10 and 15 mg/kg). @entity5633 (0.3, 1 and 3 mg/kg) was used as a negative control since the drug is effective in @entity148 but not @entity4697 . Chronically, both @entity8991 and @entity905 impaired one-escape, an antipanic-like effect, not altering avoidance latencies. @entity8991 , but not @entity905 , also affected locomotion. Acute injection of @entity5633 impaired avoidance, an anxiolytic-like effect. Neither acute nor chronic @entity5633 altered one-escape. These results corroborate the suggestion that one-way escape is related to @entity4697 .

Antipanic-like effect of XXXX reuptake inhibitors in the elevated T-maze.

@entity8991 :: ('MESH:D002997', 'Chemical') :: ['Clomipramine', 'clomipramine'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity4697 :: ('MESH:D016584', 'Disease') :: ['PD', 'panic disorder'] @entity5633 :: ('MESH:D002065', 'Chemical') :: ['buspirone', 'Buspirone'] @entity148 :: ('MESH:D001008', 'Disease') :: ['generalized anxiety', 'GAD', 'anxiety disorders'] @entity2645 :: ('MESH:D007099', 'Chemical') :: ['imipramine'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']
@entity750 :: (MESH:D012701,Chemical) :: ['serotonin']
